Drug-Eluting Stent System
*ø 2.25 – 3.0 mm
TLF – Target Lesion Failure; TV-MI – Target Vessel Myocardial Infarction; TLR – Target Lesion Revascularization.
§As characterized with respect to strut thickness in Bangalore et al. Meta-analysis.
◊Based on investigator’s interpretation of BIOFLOW-V primary endpoint results.
*Compared to Xience, based on three consecutive years.
¤p-values for 36-m frequentist analysis.
ф vs. Xience, based on 36-m frequentist analysis.
* Compared to Xience, BIOTRONIK data on file, based on the Rate Ratio of 0.59.
**BCI: Bayesian Credibility Interval.
¤ n= 1,300 newly enrolled STEMI patients including 407 patients from the BIOSCIENCE STEMI subgroup used as prior information.
‡ Driven by peri-procedural MI events (<48 hours). In-hospital rate may include events > 48 hours.
Δ Images: Secco G et al. Time-related changes in neointimal tissue coverage following a new generation SES implantation: an OCT observational study.
Presented at: euro PCR, May 20, 2014; Paris, France.
1. Kandzari D et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimuseluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017 Oct 21; 390(10105):1843-1852; 2. Kandzari D et al. Ultrathin bioresorbable polymer sirolimus-eluting stents versus thin durable polymer everolimus-eluting stents. Journal of the American College of Cardiology. 2018 Dec 17;72(25):3287-97; 3. Kandzari D et al. J Am Coll Cardiol. Cardiovasc Interven. 2020, doi: 10.1016/j.jcin.2020.02.019. 4. Iglesias JF et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial; Lancet, September, 2019; 5. Pilgrim T et al. 5-year outcomes of the BIOSCIENCE randomised trial. Supplementary appendix; Lancet 2018; published online Aug 28. http://dx.doi.org/10.1016/S0140-6736(18)31715-X; 6. Foin et al. Impact of stent strut design in metallic stents and biodegradable scaffolds. Int J Cardiol.2014 Dec 20;177(3):800-8; 7. Secco G et al. Time-related changes in neointimal tissue coverage of a novel Sirolimus eluting stent: Serial observations with optical coherence tomography. Cardiovascular Revascularization Medicine 17.1 (2016): 38-43; 8. Bangalore S et al. Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease: metaanalysis of randomized trials. Circulation. 2018 Nov 13;138(20):2216-26; 9. Bangalore S, et al. Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease: meta-analysis of randomized trials. Circulation. 2018 Jul. 24: 2216-2226; 10. Stefanini GG et al. Coronary stents: novel developments. Heart. 2014 Jul 1;100(13):1051-61; 11. Low AF. Stent platform for procedural success: Introducing the Continuous Sinusoidal & Core Wire Technologies. Presented at: AsiaPCR; 22-24 January, 2015; Singapore, Singapore; 12. Tolentino A. Evolving DES Strategy: Biodegradable Polymer vs. Bioabsorbable Scaffold. Presented at: Cardiovascular Nurse/TechnologistSymposium; June 17, 2016; New York, USA; 13. BIOTRONIK data on file.
*Indication as per IFU.
Orsiro, proBIO and BIOlute are trademarks or registered trademarks of the BIOTRONIK Group of Companies.
Synergy and Promus are trademarks or registered trademarks of the Boston Scientific group of companies. Resolute and Resolute Onyx are trademarks or registered trademarks of the Medtronic group of companies. Xience, Xience Prime and Xience Sierra are trademarks or registered trademarks of the Abbott group of companies. Ultimaster is a trademark or registered trademark of the Terumo group of companies. BioMatrix is a trademark or registered trademark of the Biosensors International Group.